MRVI — Maravai Lifesciences Holdings Income Statement
0.000.00%
Last trade - 00:00
- $2.18bn
- $2.54bn
- $288.95m
- 78
- 21
- 64
- 54
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 143 | 284 | 799 | 883 | 289 |
Cost of Revenue | |||||
Gross Profit | 76.3 | 204 | 659 | 714 | 140 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 119 | 172 | 245 | 309 | 321 |
Operating Profit | 24 | 112 | 555 | 574 | -31.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -5.85 | 81.7 | 531 | 551 | 618 |
Provision for Income Taxes | |||||
Net Income After Taxes | -5.2 | 78.8 | 469 | 491 | -138 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -2.8 | 92.2 | 182 | 220 | -119 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -8.48 | 76.9 | 402 | 426 | -119 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.033 | 0.272 | 1.53 | 1.74 | -0.72 |
Dividends per Share |